Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

by Oriol Iborra-Egea, MSc, Evelyn Santiago-Vacas, MD, Salva R. Yurista, MD, Josep Lupón, MD, PhD, Milton Packer, MD, Stephane Heymans, MD, Faiez Zannad, MD, Javed Butler, MD, Domingo Pascual-Figal, MD, Antonio Lax, PhD, Julio Núñez, MD, PhD, Rudolf A. de Boer, MD, PhD, Antoni Bayés-Genís, MD, PhD
Published 2019-11-01

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction

by Paloma Gastelurrutia, PhD, Josep Lupón, MD, PhD, Pedro Moliner, MD, Xiaobo Yang, MB, German Cediel, MD, PhD, Marta de Antonio, MD, PhD, Mar Domingo, MD, PhD, Salvador Altimir, MD, Beatriz González, CN, Margarita Rodríguez, CN, Carmen Rivas, CN, Violeta Díaz, CN, Erik Fung, MB, ChB, PhD, Elisabet Zamora, MD, PhD, Javier Santesmases, MD, Julio Núñez, MD, PhD, Jean Woo, MD, Antoni Bayes-Genis, MD, PhD, FESC
Published 2018-06-01